200,000 Shares in Vir Biotechnology, Inc. (NASDAQ:VIR) Bought by Affinity Asset Advisors LLC

Affinity Asset Advisors LLC acquired a new stake in shares of Vir Biotechnology, Inc. (NASDAQ:VIR) in the 2nd quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The firm acquired 200,000 shares of the company’s stock, valued at approximately $1,780,000. Affinity Asset Advisors LLC owned about 0.15% of Vir Biotechnology as of its most recent SEC filing.

A number of other institutional investors and hedge funds have also made changes to their positions in VIR. Caxton Associates LP purchased a new position in Vir Biotechnology during the second quarter worth $531,000. Point72 Asia Singapore Pte. Ltd. grew its holdings in Vir Biotechnology by 491.7% during the 2nd quarter. Point72 Asia Singapore Pte. Ltd. now owns 18,959 shares of the company’s stock valued at $169,000 after purchasing an additional 15,755 shares during the last quarter. Point72 Hong Kong Ltd raised its position in Vir Biotechnology by 180.6% in the 2nd quarter. Point72 Hong Kong Ltd now owns 19,572 shares of the company’s stock worth $174,000 after purchasing an additional 12,598 shares during the period. Cubist Systematic Strategies LLC raised its position in Vir Biotechnology by 6,402.0% in the 2nd quarter. Cubist Systematic Strategies LLC now owns 188,624 shares of the company’s stock worth $1,679,000 after purchasing an additional 185,723 shares during the period. Finally, Point72 DIFC Ltd lifted its stake in Vir Biotechnology by 199.9% in the second quarter. Point72 DIFC Ltd now owns 26,917 shares of the company’s stock worth $240,000 after purchasing an additional 17,941 shares during the last quarter. 65.32% of the stock is owned by hedge funds and other institutional investors.

Vir Biotechnology Trading Down 0.8 %

Shares of VIR stock opened at $7.54 on Wednesday. Vir Biotechnology, Inc. has a twelve month low of $7.41 and a twelve month high of $13.09. The stock has a fifty day simple moving average of $8.72 and a two-hundred day simple moving average of $9.31. The stock has a market capitalization of $1.03 billion, a price-to-earnings ratio of -1.88 and a beta of 0.46.

Vir Biotechnology (NASDAQ:VIR) last announced its quarterly earnings results on Thursday, August 1st. The company reported ($1.02) earnings per share for the quarter, missing the consensus estimate of ($0.89) by ($0.13). The business had revenue of $3.08 million during the quarter, compared to analysts’ expectations of $7.53 million. Vir Biotechnology had a negative return on equity of 30.93% and a negative net margin of 612.40%. Vir Biotechnology’s revenue for the quarter was down 19.0% on a year-over-year basis. During the same period in the previous year, the company posted ($1.45) EPS. Research analysts predict that Vir Biotechnology, Inc. will post -3.26 EPS for the current fiscal year.

Insider Transactions at Vir Biotechnology

In other Vir Biotechnology news, Director Janet Napolitano sold 12,190 shares of Vir Biotechnology stock in a transaction dated Monday, September 9th. The stock was sold at an average price of $7.80, for a total value of $95,082.00. Following the transaction, the director now owns 11,616 shares in the company, valued at $90,604.80. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website. Corporate insiders own 15.60% of the company’s stock.

Wall Street Analyst Weigh In

A number of equities research analysts recently issued reports on VIR shares. Needham & Company LLC raised their price target on Vir Biotechnology from $15.00 to $19.00 and gave the stock a “buy” rating in a research note on Wednesday, June 5th. Barclays boosted their target price on shares of Vir Biotechnology from $27.00 to $28.00 and gave the company an “overweight” rating in a research note on Friday, August 2nd. HC Wainwright reaffirmed a “buy” rating and issued a $110.00 price target on shares of Vir Biotechnology in a research note on Tuesday, August 20th. Finally, Morgan Stanley lifted their price objective on shares of Vir Biotechnology from $12.00 to $15.00 and gave the company an “equal weight” rating in a report on Thursday, June 6th. Two research analysts have rated the stock with a hold rating and three have issued a buy rating to the stock. Based on data from MarketBeat, the stock currently has an average rating of “Moderate Buy” and an average price target of $36.80.

Vir Biotechnology Profile

Vir Biotechnology, Inc, a commercial-stage immunology company, develops therapeutic products to treat and prevent serious infectious diseases. It offers tobevibart + elebsiran for the treatment of chronic hepatitis delta; elebsiran + PEG-IFN-a, tobevibart ± elebsiran ± PEG-IFN-a, and elebsiran+ TLR8+PD-1 for the treatment of chronic hepatitis B; VIR-1388 and Cure mAb combination for the treatment of human immunodeficiency virus; VIR-8190 for the treatment of respiratory syncytial virus / human metapneumovirus; VIR-2981 for the treatment of influenza; VIR-1949 for the treatment of pre-cancerous HPV lesions; and VIR07229 and Sotrovimab for the treatment of COVID-19 infection under the Xevudy brand.